Osimertinib Active Not Recruiting Phase 1 Trials for Lung Cancer Non-Small Cell Cancer (NSCLC) Treatment

IndicationsStatusPurposePhase
Active Not RecruitingTreatment1
clinicaltrials.gov IdentifierTitleDrugs
NCT02789345A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer
NCT02908750Study to Assess the Effect of Osimertinib (TAGRISSO™ ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC